Guo ZS - Search Results

1

Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy.

Guo ZS, Lotze MT, Zhu Z, Storkus WJ, Song XT. Guo ZS, et al. Biomedicines. 2020 Jul 10;8(7):204. doi: 10.3390/biomedicines8070204. Biomedicines. 2020. PMID: 32664210 Free PMC article. Review.

2

The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2.

Guo ZS, Naik A, O'Malley ME, Popovic P, Demarco R, Hu Y, Yin X, Yang S, Zeh HJ, Moss B, Lotze MT, Bartlett DL. Guo ZS, et al. Cancer Res. 2005 Nov 1;65(21):9991-8. doi: 10.1158/0008-5472.CAN-05-1630. Cancer Res. 2005. PMID: 16267024

3

High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists.

Popovic PJ, DeMarco R, Lotze MT, Winikoff SE, Bartlett DL, Krieg AM, Guo ZS, Brown CK, Tracey KJ, Zeh HJ 3rd. Popovic PJ, et al. Among authors: guo zs. J Immunol. 2006 Dec 15;177(12):8701-7. doi: 10.4049/jimmunol.177.12.8701. J Immunol. 2006. PMID: 17142771

4

Life after death: targeting high mobility group box 1 in emergent cancer therapies.

Guo ZS, Liu Z, Bartlett DL, Tang D, Lotze MT. Guo ZS, et al. Am J Cancer Res. 2013;3(1):1-20. Epub 2013 Jan 18. Am J Cancer Res. 2013. PMID: 23359863 Free PMC article.

5

Oncolytic viruses as therapeutic cancer vaccines.

Bartlett DL, Liu Z, Sathaiah M, Ravindranathan R, Guo Z, He Y, Guo ZS. Bartlett DL, et al. Among authors: guo z, guo zs. Mol Cancer. 2013 Sep 11;12(1):103. doi: 10.1186/1476-4598-12-103. Mol Cancer. 2013. PMID: 24020520 Free PMC article. Review.

6

T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy.

Yu F, Wang X, Guo ZS, Bartlett DL, Gottschalk SM, Song XT. Yu F, et al. Among authors: guo zs. Mol Ther. 2014 Jan;22(1):102-11. doi: 10.1038/mt.2013.240. Epub 2013 Oct 17. Mol Ther. 2014. PMID: 24135899 Free PMC article.

7

Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives.

Guo ZS, Liu Z, Kowalsky S, Feist M, Kalinski P, Lu B, Storkus WJ, Bartlett DL. Guo ZS, et al. Front Immunol. 2017 May 15;8:555. doi: 10.3389/fimmu.2017.00555. eCollection 2017. Front Immunol. 2017. PMID: 28555136 Free PMC article. Review.

8

Editorial of the Special Issue: Oncolytic Viruses as a Novel Form of Immunotherapy for Cancer.

Guo ZS, Bartlett DL. Guo ZS, et al. Biomedicines. 2017 Aug 24;5(3):52. doi: 10.3390/biomedicines5030052. Biomedicines. 2017. PMID: 28837095 Free PMC article.

9

Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.

Guo ZS, Lu B, Guo Z, Giehl E, Feist M, Dai E, Liu W, Storkus WJ, He Y, Liu Z, Bartlett DL. Guo ZS, et al. Among authors: guo z. J Immunother Cancer. 2019 Jan 9;7(1):6. doi: 10.1186/s40425-018-0495-7. J Immunother Cancer. 2019. PMID: 30626434 Free PMC article. Review.

10

Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy.

Feist M, Zhu Z, Dai E, Ma C, Liu Z, Giehl E, Ravindranathan R, Kowalsky SJ, Obermajer N, Kammula US, Lee AJH, Lotze MT, Guo ZS, Bartlett DL. Feist M, et al. Among authors: guo zs. Cancer Gene Ther. 2021 Feb;28(1-2):98-111. doi: 10.1038/s41417-020-0189-4. Epub 2020 Jul 7. Cancer Gene Ther. 2021. PMID: 32632271 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

143 results

Search Page